

Frequency of Variants in Mendelian Alzheimer's Disease Genes within the Alzheimer's Disease Sequencing Project (ADSP)

Dongyu Wang, MS, MPH^{1*}, Alexandra Scalici, MPH^{1*}, Yanbing Wang, PhD¹, Honghuang Lin, PhD², Achilleas Pitsillides¹, PhD, Nancy Heard-Costa, PhD^{3,4}, Carlos Cruchaga, PhD⁵⁻⁸, Ellen Ziegemeier, MA⁸, Joshua C. Bis, PhD⁹, Myriam Fornage, PhD¹⁰, Eric Boerwinkle, PhD^{11,12}, Philip L De Jager, MD^{13,14}, PhD, Ellen Wijsman, PhD^{15,16}, Josée Dupuis, PhD¹, Alan E. Renton, PhD^{17,18}, Sudha Seshadri, MD^{4,19,20}, Alison Goate, DPhil^{17,18}, The Alzheimer's Disease Sequencing Project, Anita L. DeStefano, PhD^{1,4*}, Gina M. Peloso, PhD^{1*}

1. Department of Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA.
2. Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01655, USA.
3. Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA.
4. NHLBI Framingham Heart Study, Framingham, Massachusetts, 01702, USA.
5. Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
6. Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA.
7. NeuroGenomics and Informatics, Washington University School of Medicine, St. Louis, Missouri, USA.
8. Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
9. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, 98195, USA.
10. Brown Foundation Institute of Molecular Medicine, McGovern Medical School and Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.
11. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.
12. Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
13. Center for Translational & Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA.
14. Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.
15. Department of Biostatistics, University of Washington, Seattle, WA, USA, 98195.
16. Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
17. Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

18. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
19. Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
20. Glenn Biggs Institute for Alzheimer's Disease and Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, TX, USA.

*These authors contributed equally.

Corresponding author:

Gina Peloso

gpeloso@bu.edu

Statistical Analysis was conducted by Dongyu Wang, MS, MPH, Alexandra Scalici, MPH and Dr. Gina Peloso, PhD at Boston University School of Public Health

Disclosures:

AMG has consulted for Eisai, Biogen, AbbVie, and GSK; she also serves on the Scientific Advisory Boards of Genentech and Muna Therapeutics. All other authors report no disclosures relevant to this manuscript.

Acknowledgements: This work was supported in part by NIA grant U01AG058589.

ABSTRACT

Objective: To characterize the consequences of loss-of-function (LoF), predicted damaging missense (DM), and previously-reported clinically-relevant variants in three Mendelian Alzheimer's disease (AD) genes – presenilin-2 (*PSEN2*), presenilin-1 (*PSEN1*), and amyloid precursor protein (*APP*) – within the participants from the Alzheimer's Disease Sequencing Project (ADSP) whole genome sequence (WGS) and whole exome sequence (WES) data.

Methods: We identified rare variants (MAF <1%) previously-reported in *PSEN2*, *PSEN1*, and *APP* in the available ADSP sample of 14,641 individuals with WGS and 16,849 individuals with WES available for research-use ($N_{\text{total}} = 31,490$). We additionally curated variants in these three genes from ClinVar, OMIM, and Alzforum and report carriers of variants in clinical databases as well as LoF and predicted DM variants in these genes.

Results: We detected 31 previously-reported clinically-relevant variants with alternate alleles observed within the ADSP: 4 variants in *PSEN2*, 25 in *PSEN1*, and 2 in *APP*. Thirty-eight clinical variants with conflicting pathogenicity interpretation within ClinVar or across the databases were identified along with 12 additional LoF and 197 additional DM variants. The overall variant carrier rate for the 31 clinically-relevant variants in the ADSP was 0.3%. We observed 78 individuals carrying at least one clinically-relevant variant, 79.5% were cases compared to 3.9% controls. In those with AD, we observed that the mean age of onset of AD among carriers of these clinically-relevant variants was 19.6 ± 1.4 years earlier compared with non-carriers ($p\text{-value}=7.8 \times 10^{-57}$), and the average age of onset of AD is 5 years earlier in carriers of an additional LoF variant ($n=5$) compared with non-carriers.

Conclusion: The ADSP data permit further characterization of previously-reported AD clinically-relevant variants. A small proportion of individuals in the ADSP are carriers of a

previously-reported clinically-relevant variant allele for AD and these participants have significantly earlier age of AD onset compared to non-carriers. Furthermore, we observed additional LoF variants that potentially contribute to clinical presentation of AD.

INTRODUCTION

Mendelian Alzheimer's disease (AD) makes up less than 1% of all AD cases and is characterized by an early age of onset (<65 years old).¹ Rare mutations in the *PSEN1*, *PSEN2*, and *APP* genes have been previously characterized to show Mendelian AD inheritance patterns within families.¹ Identification and classification of variants in these three genes has aided both in the molecular classification of pathways involved in AD pathogenesis and screening for known AD causing variants within families. Variants within these three genes show an autosomal dominant inheritance pattern with near complete penetrance.¹ Publicly available clinical databases such as ClinVar, Online Mendelian Inheritance of Man (OMIM), and Alzforum have compiled clinically-relevant variants presumed to cause AD and other types of dementia ("clinical variants"). These databases are important resources but also have limitations. For example, variants identified in the 1990s may have only had few controls to determine their clinical relevance. Additionally, variants shown to be Mendelian with assumed near complete penetrance may also be found in late onset familial and sporadic AD as part of more comprehensive screening strategies that have less biased ascertainment than the highly-selected, large pedigrees used originally to identify these genes leading to conflicting interpretations of clinical variants.^{2,3}

The Alzheimer's Disease Sequencing Project (ADSP) seeks to identify novel genetic risk factors for AD. The data collected and generated through the ADSP consist of whole genome sequence (WGS) and whole exome sequence (WES) data from family, case-control, and cohort study designs.⁴ Within the ADSP, standardized variant calling and data management pipelines (VCPA), as well as an ADSP Quality Control (QC) protocol have been implemented.^{5,6} Bringing together high-quality sequence data from across the AD research community has allowed for an

increased sample size, overall increasing statistical power and the ability to search for rare variation associated with AD. Given that ADSP data are biased towards the selection of variants of incomplete penetrance, we aimed to leverage these data to further characterize previously-reported AD clinical variants.

Previously, two studies using a prior release of ADSP data examined variants within *APP*, *PSEN1*, *PSEN2*, and other dementia related genes.^{7,8} With a newer release and doubled sample size, we seek to examine the frequency of previously-reported clinically-relevant and conflicting clinically-relevant variants as well as predicted loss-of-function (LoF) and damaging missense (DM) variants in these three Mendelian AD genes within the ADSP WES and WGS datasets. We report on the distribution of these variants by racial and ethnic group to clarify the clinical implications of these previously-reported variants in the context of a history of disparity in representation in most studies of AD. Knowing the distribution of these variants in the ADSP datasets, which are publicly accessible to qualified researchers, may also inform studies focused on gene and variant identification at other loci in the context of AD risk.

METHODS

ADSP study data

WES and WGS data have been generated in multiple cohorts as part of the ADSP. See **Supplementary Methods** for description of the data included in this manuscript. Study participants provided written informed consent per each study's Institutional Review Board (IRB) approved protocol. These data were analyzed through a protocol approved by the Boston University IRB.

The release of the ADSP data used in the current study contains 16,905 samples with WGS data (NG00067.v3) and 20,504 samples with WES data (NG00067.v3). Genetically identical individuals were identified based on pairwise scaled KING kinship coefficient ≥ 0.354 as recommended by the PLINK2.0 documentation.⁹ Keeping one genetically unique participant and preferentially selecting WGS over WES yielded 31,490 individuals (14,641 with WGS and 16,849 with WES) with both genotype and phenotype information. QC flags in the ADSP files were used in a filtering process to retain high quality variants as detailed in the supplemental materials.

Phenotype determination

For participants in the ADSP case-control study, we defined AD cases as individuals with either prevalent or incident AD. ADSP case-control study participants with no prevalent or incident AD were defined as controls. Participants with a status of “NA” were recoded as “Unknown”. In the ADSP family studies, the AD status variable has the possible values of no dementia, definite AD, probable AD, possible AD, family-reported AD, other dementia, family-reported no dementia, and unknown. For ADSP family-based study participants, we defined AD cases as individuals coded with possible, probable, or definite AD. AD controls were defined as individuals coded as no dementia. Participants with a status of family-reported AD, other dementia, and unknown were all recoded as “Unknown” for AD status. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) phenotype data, which is part of the ADSP augmentation study, provides information on mild cognitive impairment (MCI) in addition to AD status. Individuals with a current diagnosis of MCI were set to AD unknowns (N=313) in the current study. Age of onset was available in

98% (13,491 of 13,825) of the AD cases. Participants with age greater than 90 (“90+”) were recoded to 90 to create a continuous age variable. Individuals with reported race as Asian, Native Hawaiian or Pacific Islander, American Indian or Alaskan Native, Other, or Unknown were combined and classified as Other/Unknown (N=4,725).

Curation of clinically-relevant variants

Variants previously-reported in *PSEN2*, *PSENI*, *APP* were aggregated from ClinVar¹⁰ (June 2023), Online Mendelian Inheritance in Man¹¹ (OMIM, June 2023), and Alzforum¹² (March, 2023), which we label as “clinical variants”. Variants were selected and classified as clinical variants if they were described as pathogenic or likely pathogenic, and related to AD, dementia, or a related disorder in any of the databases (**Supplementary Table e-1**). For variants with conflicting interpretations of pathogenicity in ClinVar, or having conflicting pathogenicity across the databases, we created a separate list and referred to the variants as “conflicting clinical variants”. Variants with minor allele frequency < 1% that met these criteria were selected within the WGS and WES using PLINK 2.0.¹³ Variants were matched based on chromosome, position, reference allele, and alternate allele. Alternate allele is defined as the mutant allele as compared to the reference allele and individuals carrying an alternate allele of at least one clinical or conflicting clinical variant are termed clinical variant carriers or conflicting clinical variant carriers, respectively, in this study.

Variant annotation

Variants in *PSEN2*, *PSENI*, *APP* with minor allele frequency < 1% within ADSP were selected and annotated using Ensembl Variant Effect Predictor (VEP) release 108 using default parameter

and human genome reference build 38.¹⁴ A LoF variant was defined as having any of the following prediction consequences: splice acceptor variant, splice donor variant, stop gained, or frameshift variant. Any other variants with missense consequence and a damaging metaSVM prediction from the database for non-synonymous functional prediction (dbNFSP) version 4.3a were classified as damaging missense (DM) variants.^{15,16} Individuals who carry at least one LoF/DM variant that is not in the curated clinical variant list are classified as additional LoF/DM variant carriers. One individual was identified as both a LoF variant carrier and a DM variant carrier, and we preferentially coded that individual as an additional LoF variant carrier. Additionally, we annotated the clinical variants within ADSP using the InterVar tool and obtained the gnomAD allele frequencies using the allele frequencies from the exomes control set as well as InterVer pathogenicity predictions.¹⁷ We restricted to the control individuals for reporting the gnomAD allele frequencies given that ADSP contributed to gnomAD.

Statistical analysis

The ADSP phenotype and genotype data were used to identify individuals carrying at least one alternate allele for a clinical variant or a LoF/DM variant and generate descriptive statistics based on carrier status and AD diagnosis. In order to examine the distribution of genetic variants across different populations, we defined population groups based on reported race and ethnicity. We compared the mean age of onset of AD by carrier status using a linear mixed regression model with carrier status as the exposure and age of onset as the outcome, adjusting for sex and the first four principal components of ancestry, accounting for an empirical Balding-Nichols kinship matrix. All statistical analyses were performed using R 4.2.1. A schematic of the analysis is shown in **Figure 1**.

Data availability

ADSP whole genome (NG00067.v3) and whole exome (NG00067.v3) sequencing data are available through The National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIGADS) (<https://www.niagads.org/>).

RESULTS

Aggregating variants in ClinVar, OMIM, and Alzforum that met our criteria yielded a list of 293 clinical variants and 51 conflicting clinical variants, totaling 344 variants: 29 in *PSEN2*, 251 in *PSEN1*, and 64 in *APP* (**Supplementary Table e-2**). After removing genetically identical individuals, we had a total of 31,490 individuals consisting of 13,825 AD cases, 14,715 controls, and 2,950 with unknown AD status (**Table 1**). We identified 78 individuals that carried at least one clinical variant, 550 individuals that carried at least one conflicting clinical variant, 12 individuals that carried at least one additional LoF variant, and 843 individuals that carried at least one additional DM variant (**Table 1**).

Among the 293 variants from the aggregated list of clinical variants, 31 had alternate alleles present within the ADSP data: 4 in *PSEN2*, 25 in *PSEN1*, and 2 in *APP* (**Table 2**). All 31 variants seen within the ADSP participants are coding variants and were rare within the ADSP (MAF <1%). Overall, 78 ADSP participants (0.3%) carry at least one alternate allele of the variants curated from the clinical databases (**Table 2**). The 78 clinical variant carriers consisted of 5 LoF variant carriers and 73 DM variant carriers. *PSEN1* variant carriers constituted the greatest proportion (0.22%) of the clinical variant carriers, followed by *PSEN2* variant carriers

(0.02%) and *APP* variant carriers (0.01%). One pair of related individuals have a *PSEN1* (rs63750082, p.Gly206Ala) variant, and we inferred that they are siblings based on kinship coefficient (0.24) and age (57 and 64 years old, respectively) and are a part of the ADSP Family study. Within the group of 78 individuals carrying at least one clinical variant, as expected, most were AD cases (N=62, 79%) or those with unknown AD status (N=13, 17%); very few were controls (N=3, 4%). Non-Hispanic White participants have the highest proportion of clinical variant carriers (59%) and are the largest proportion of the data (67%), whereas Non-Hispanic Blacks constitute 16.8% of the data, but are only 3.9% of the clinical variant carriers (**Table 1**).

The higher number of clinical variant carriers in cases compared to controls was consistent across the three genes. We observed the highest proportion of clinical variant carriers among cases for *PSEN1*, with 0.4% of the AD cases carrying a clinical variant as compared to 0.01% of the controls (**Table 3**). Among *PSEN2* carriers, 0.03% of those who were diagnosed with AD carry an alternate allele in *PSEN2* variants compared to 0.01% of controls. And *APP* carrier rate is 0.01% in the AD cases as compared to 0% in the controls. Noteworthy, the higher proportion of *PSEN1* carriers among the cases are mainly due to two variants: rs63749824 (p.Ala79Val) and rs63750082 (p.Gly206Ala) (**Table 4**). When restricting controls to more advanced ages (>65 or > 85), we observed similar carrier rates between cases and elder controls for clinical variant carriers of all 3 genes (**Table 3**).

We observed 38 out of 51 conflicting clinical variants, which consist of 13 *PSEN2* variants, 9 *PSEN1* variants, and 16 *APP* variants among the ADSP participants (**Table 2**). There were 550 individuals (1.75%) carrying at least one alternate allele of a conflicting clinical variant within

the ADSP datasets, of which 240 are *PSEN2* variant carriers (0.76%), 88 are *PSENI* variant carriers (0.28%), and 222 are *APP* variant carriers (0.70%) (**Table 2**). There were 57 related individuals among the conflicting clinical variant carriers. Among the conflicting clinical variant carriers, we observed a higher percentage of controls (N=270, 49.09%) than cases (N=224, 40.73%). Non-Hispanic White individuals (65.45%) constituted the largest proportion of the conflicting clinical variant carriers, followed by Non-Hispanic Black (17.27%), Non-Hispanic Other/Unknown (0%), Hispanic White (1.09%), Hispanic Black (0.18%), and Hispanic Other/Unknown individuals (16%) (**Table 1**).

We observed that the rates of conflicting clinical variant carriers are higher in controls for *PSEN2* and *APP* variants, with 0.80% and 0.76% of the controls carrying at least one conflicting clinical variant as compared to 0.69% and 0.64% of the cases, respectively. The rates for *PSENI* conflicting clinical variant carriers were 0.27% of the controls were *PSENI* variant carriers in contrast to 0.29% of the cases. And the rates of conflicting variant carriers increased when looking at elder controls except for *PSENI* variant carriers (**Table 3**). We observed 23 variants that were seen more often in controls rather than cases: 11 in *PSEN2*, 5 in *PSENI*, and 7 in *APP*, of which 5 variants were only seen in controls (rs201269325, p.Gly709Ser; rs63750831 p.Val94Met; rs115760359, p. Pro218Pro; rs63750227 p.Ala409Thr; rs866044092 p.Val150Met) (**Supplementary Table e-3**). Out of the 38 conflicting clinical variants, 27 of the conflicting clinical variants were all observed in both cases and controls, diminishing support for these variants (**Supplement Table e-3**).

Using VEP to annotate rare variants (MAF <1%) observed in the ADSP participants, we identified 12 additional LoF variants in the 3 genes that had not been previously identified as a clinical or conflicting clinical variant: 5 in *PSEN2*, 1 in *PSEN1*, and 6 in *APP* (**Supplement Table e-4**). Twelve participants were identified as additional LoF variant carriers: 6 are *PSEN2* variant carriers, 1 is *PSEN1* variant carrier, and 5 are *APP* variant carriers (**Table 2**). One additional LoF variant carrier has two LoF variants in *APP* (rs1568829407, p. Asp360LeufsTer50 and rs1568829384, p. Val362ThrfsTer10). Additionally, 197 rare variants (MAF < 1%) within ADSP were predicted to be additional DM variants (**Supplement Table e-5**). Eighty-three out of the 197 additional DM variants were found in *PSEN2* with another 45 in *PSEN1* and 69 in *APP* (**Table 2**). The frequency of DM variant carriers is much higher than that of clinical, conflicting clinical, or LoF variant carriers, with 843 participants carrying at least one alternate allele of the predicted DM variants. Specifically, 382 participants carry DM variants in *PSEN2*, 74 carry DM variants in *PSEN1*, and 387 carry DM variants in *APP*. And 100 individuals of all the additional DM variant carriers were first-degree relatives evaluated via the kinship coefficients. Among the 12 the additional LOF variant carriers, 5 individuals were AD cases, 3 were controls, and another 4 with AD unknown status. This difference was reversed in the additional DM variant carriers since there were more controls than cases (43.30% vs 48.40%, **Table 1**).

The rate of carrying additional LoF variants in the *APP* gene was similar among cases and controls. Four AD cases were identified as carrying an additional LoF variant in the *PSEN2* gene while only one control had a *PSEN2* additional LoF variant (**Table 3**), suggesting these may be additional functional *PSEN2* variants. The frequency of additional DM variants in controls

indicates that this class of variation is too diverse for identifying additional functional DM variants. Overall, the low clinical/LoF/DM variant carrier rates within ADSP participants suggest that it's extremely unlikely for controls who are greater than 60 years old to be a carrier of a pathogenic Mendelian AD variant (**Table 3**).

The carrier rate varied by NIAGADS defined study sites (**Supplementary Table e-6**), with highest carrier rates in a family study and a sample of individuals selected based on family history (the “enriched” sample within the ADSP Discovery case/control set). Because family history of AD is not available across the ADSP study, we were not able to evaluate the carrier rate by presence or absence of family history.

The ADSP samples included in this analysis are predominantly Non-Hispanic White (66.9%), followed by Non-Hispanic Black (16.85%), Hispanic White (1.02%), Hispanic Black (0.23%), Hispanic Other/Unknown (14.68%), and Non-Hispanic Other/Unknown (0.32%). None of the clinical variant carriers were of Non-Hispanic Other/Unknown population, and the lowest observed carrier rate was found among individuals reported as Hispanic Black (0.003%) compared to Non-Hispanic White (0.15%), Non-Hispanic Black (0.01%), Hispanic White (0.04%), , or Hispanic Other/Unknown (0.05%) (**Supplementary Table e-7**). Within each population, cases have a higher clinical variant carrier rate compared to the controls (**Supplementary Table e-7**).

We examined whether carrying an alternate allele of one of the curated variants is associated with the age of onset of AD. Among participants with AD and available age of onset data, we

observed 62 clinical variant carriers, 5 additional LoF variant carriers, 224 conflicting clinical variant carriers, 365 additional DM carriers, and 13,169 non-carriers. The mean age of onset of AD among clinical variant carriers was significantly lower (55.6 ± 10.9 range 34-76 years) than the mean age of onset in the non-carriers (75.6 ± 9.5 range 39-90 years) when accounting for relatedness among participants (score test $p\text{-value}=7.8 \times 10^{-57}$, **Figure 2**). Since we only observed 5 additional LoF variant carriers with age of onset, we collapsed the clinical variant carriers with additional LoF variant carriers and tested the difference in the mean age of onset between the clinical+LoF variant carriers and the non-carriers, and we observed a significant difference (score test $p\text{-value}= 1.1 \times 10^{-54}$, **Figure 2**). However, interpretation of these results must be placed in the context of the age-based risk score used for selection of a portion of the subjects included in the ADSP dataset.

When looking at the *APOE* allele distribution in clinical variant carriers and non-carriers, we found 1 control and 20 cases who carry at least one *APOE* $\epsilon 4$ allele among the clinical variant carriers. Six clinical variant carriers who were diagnosed with AD carry one *APOE* $\epsilon 2$ allele whereas none of the control clinical variant carriers were *APOE* $\epsilon 2$ carriers indicating they may harbor another protective variant. The *APOE* $\epsilon 3/\epsilon 3$ genotype is the most prevalent genotype both in cases and controls among the clinical variant carriers. There is a higher proportion of *APOE* $\epsilon 2$ allele carriers in the controls (15.8%) as compared to cases (8.1%) among the clinical variant non-carriers. Conversely, more cases (50.3%) were seen compared to controls (26.5%) among the *APOE* $\epsilon 4$ allele carriers (**Supplementary Table e-8**). *APOE* genotype was part of the case selection criterion for the WES case-control study, which can lead to an inverted association of *APOE* $\epsilon 4$ in some sets of individuals (i.e., cases selected without known genetic risk and controls

who avoided AD despite known genetic risk). We didn't observe any statistical evidence for potential protective or synergic effect by the *APOE* ϵ alleles with the clinical variant carriers of the 3 Mendelian genes, however, this might be due to limited clinical carrier counts hence we lack the power to formally test the gene by gene interaction on AD.

DISCUSSION

Two studies using a prior release of ADSP data examined variants within *APP*, *PSENI*, *PSEN2*, and other dementia related genes.^{7,8} Blue et al examined 578 WGS and 10,836 WES samples and Fernandez et al examined 143 WGS and 10,280 WES samples from the ADSP. The current study, using a more recent data release, doubles the sample size over the prior studies and increases the diversity among the study participants.

We identified variants in the *PSEN2*, *PSENI*, and *APP* genes previously implicated in Mendelian AD within the ADSP WES and WGS data sets. Among clinical variant carriers overall, a higher proportion were cases compared to controls. However, some previously reported clinical variants were observed in control individuals. This may reflect the age of the carrier. Clinical variant carriers who were controls had ages of 73, 74, and 90 and some of these individuals may manifest AD in the future. Our observation of clinical variants in controls may also reflect reduced penetrance or the misclassification of a variant as clinically relevant for AD. Within the ADSP, AD cases were more likely to be carrying clinical variants in *PSEN2*, *PSENI* or *APP* (0.03%, 0.41% and 0.01%, respectively) compared to controls (**Table 3**). However, we observed higher proportions of controls carrying conflicting clinical variants in *PSEN2* and *APP* (**Table**

3). This could be explained by varying penetrance of the variants or that these variants are potentially not causal for AD.

Four conflicting clinical variants were labeled as pathogenic/likely pathogenic in either OMIM or Alzforum but not in ClinVar (rs63750197 *PSEN2* p.Ser130Leu, rs63750831 *PSEN1* p.Val94Met, rs63750847 *APP* p.Ala673Thr, rs63750363 *APP* p. Glu665Asp) (**Supplementary Table e-3**). Arboleda-Velasquez et al reported the protective effect of the *APOE3ch* mutation (rs121918393.p.Arg154Ser) against a *PSEN1* variant (rs63750231.p. Glu280Ala).¹⁸ However, both the *APOE3ch* and *PSEN1* variants were not present in our ADSP sample. In a recent report, Xian et al re-evaluated 452 pathogenic variants in *PSEN1*, *PSEN2*, and *APP* genes from PubMed and Alzforum according to the ACMG-AMP guidelines and found 5.09% of the variants were of uncertain significance.¹⁹ Altogether, these studies support the hypothesis that there is misclassification or reduced penetrance of the pathogenic/likely pathogenic variants from ClinVar, OMIM, and Alzforum, and that our data can aide in reclassifying these variants.

We observed that the mean age of onset for clinical variant carriers was significantly earlier than for non-carriers and individuals with an additional LoF variant had a mean age of onset lower than non-carriers, suggesting that the additional LoF variants may be of clinical relevance. However, this result should be interpreted with caution given distinct ascertainment schemes in different phases of the ADSP, some of which included exclusion thresholds for age at onset. Onset in the 4th and 5th decade of life was seen in individuals who did not carry an alternate allele at an identified clinical variant, suggesting that additional variants, potentially in other genes, driving early onset AD have yet to be identified.

Although the ADSP participants used in this analysis are predominantly Non-Hispanic White, a substantial proportion (33.1%) of the subjects are reported as other races/ethnicities, primarily Non-Hispanic Black and Hispanic. The carrier rates for the clinical variants were not similar among defined populations. The highest carrier rate was present among Non-Hispanic White individuals and the lowest carrier rate among participants from the Non-Hispanic Other/Unknown population (0.15% and 0%, respectively) (**Supplementary Table e-7**). Previous studies have shown that disparities in inclusion in genomic sequencing may result in misclassification or a higher rate of variants of uncertain significance for patients in underrepresented populations.²⁰ A study conducted on assessing the underlying genetic risk for hypertrophic cardiomyopathy showed that variants that had been classified as pathogenic were actually common variants in the African American population.²¹ These variants were misclassified as pathogenic due to the lack of African American controls in previous studies, emphasizing the importance of including diverse ancestry groups in order to avoid health disparities as a result of misdiagnosis.²¹ Another study showed that the sample sizes of most non-White populations within The Cancer Genome Atlas were not sufficient to detect common variants across several cancer types specific to different racial and ethnic groups.²² These studies demonstrate the importance of including diverse populations in genetic studies in order to aid in accurate disease diagnosis and treatment. Further investigation is needed to determine if the differences in clinical variant carrier rates among populations within the ADSP is due to a true difference in the frequency of AD causal *PSEN2*, *PSEN1*, *APP* variants across populations, reflects study design including ascertainment criteria, higher propensity for clinical variant screening for these three genes in White participants, or limitations due to populations

historically included in genetic studies of AD. The emphasis of the ADSP on increased diversity of study participants will help to answer some of these questions.

There were 2,950 individuals with unknown AD status in our study sample, out of which we identified 13 clinical variant carriers, 56 conflicting clinical variant carriers, 4 additional LoF variant carriers, and 70 additional DM variant carriers (**Supplementary Table e-9**). 16.7% of the clinical variant carriers had unknown AD status compared to 3.85% being as controls, indicating a mixture of potential AD cases and controls among the AD unknown individuals (**Table 1**). Upon further examination of the phenotypic data, 775 individuals out of the 2,950 do not have any phenotypic data, 313 individuals from the ADNI study had mild cognitive impairment (MCI), 549 individuals were diagnosed with progressive supranuclear palsy (PSP) while 332 individuals had corticobasal degeneration (CBD), an additional 202 individuals were from family studies, with another 779 individuals enrolled from ADSP case-control studies (**Supplementary Table e-10**).

In conclusion, we identified variants in the *PSEN2*, *PSEN1*, *APP* genes within the ADSP WES and WGS datasets. These data confirm previously-reported clinical variants, identifies additional LoF variants implicated in AD within these three Mendelian AD genes, and suggests conflicting clinical variants that may not be causal for AD. The ADSP generates WES and WGS data sets that are jointly called and QC'ed across studies. These genomic files, along with phenotype files that include AD status, are available to qualified researchers to facilitate the discovery of variants that are protective for or confer risk for AD. Understanding the presence of known Mendelian

AD variants within these data may inform analyses of variants at other loci in relation to AD risk.

Table 1. Alzheimer Disease and Demographics by Carrier Status.

	Clinical Variant Carriers	Conflicting Clinical Variant Carriers	Additional LoF Variant Carriers	Additional DM Variant Carriers	Total (%)
N	78	550	12	843	31,490
AD Diagnosis					
Case	62 (79.5%)	224 (40.7%)	5 (41.7%)	365 (43.3%)	13,825 (43.9%)
Control	3 (3.9%)	270 (49.1%)	3 (25.0%)	408 (48.4%)	14,715 (46.7%)
Unknown	13 (16.7%)	56 (10.2%)	4 (33.3%)	70 (8.3%)	2,950 (9.4%)
Sex					
Male	42 (53.9%)	200 (36.4%)	5 (41.7%)	322 (38.2%)	12,256 (38.9%)
Female	36 (46.2%)	350 (63.6%)	7 (58.3%)	521 (61.8%)	19,234 (61.1%)
Ethnicity/Race					
Non-Hispanic					
White	46 (59.0%)	360 (65.5%)	10 (83.8%)	364 (43.2%)	21,083 (67.0%)
Black	3 (3.9%)	95 (17.3%)	0 (0%)	295 (35.0%)	5,286 (16.8%)
Other/Unknown	0 (0%)	0 (0%)	1 (8.3%)	4 (0.47%)	102 (0.3%)
Hispanic					
White	12 (15.4%)	6 (1.1%)	1 (8.3%)	7 (0.8%)	322 (1.0%)
Black	1 (1.3%)	1 (0.2%)	0 (0%)	6 (0.7%)	74 (0.2%)
Other/Unknown	16 (20.5%)	88 (16.0%)	0 (0%)	167 (19.8%)	4623 (14.7%)

Data shown as frequency (percentage).

LoF: Loss-of-function; DM: Damaging missense.

Table 2. Frequency of Previously-reported Clinical Variants and Predicted Loss-of-function/Damaging Missense Variants within ADSP.

Gene	Clinical		Conflicting Clinical		Additional LoF		Additional DM	
	Variants	Carriers (% in the total sample)	Variants	Carriers (% in the total sample)	Variants	Carriers (% in the total sample)	Variants	Carriers (% in the total sample)
<i>PSEN2</i>	4	6 (0.02%)	13	240 (0.8%)	5	6 (0.02%)	83	382 (1.2%)
<i>PSEN1</i>	25	70 (0.2%)	9	88 (0.3%)	1	1 (0.003%)	45	74 (0.2%)
<i>APP</i>	2	2 (0.01%)	16	222 (0.7%)	6	5 (0.02%)	69	387 (1.2%)
Total	31	78 (0.3%)	38	550 (1.8%)	12	12 (0.04%)	197	843 (2.7%)

Data shown as frequency (percentage).

LoF: Loss-of-function; DM: Damaging missense.

Clinical variants were reported in any of ClinVar, OMIM, and Alzforum.

Clinical variant carriers include 5 LoF variant carriers, and 73 DM variant carriers.

1 additional LoF variant carrier was also identified as an additional DM variant carrier.

1 APP additional LoF carrier carries two APP LoF variants (rs1568829407, p. Asp360LeufsTer50 and rs1568829384, p. Val362ThrfsTer10).

1 APP conflicting clinical variant carrier also carries a PSEN1 clinical variant.

Related individuals were identified among the variant carriers: 2 in clinical variant carriers, 57 in conflicting clinical variant carriers, and 100 in additional DM carriers.

Table 3. Distribution of AD Diagnosis by Gene Among the Carriers.

Gene		Case (%)	Control (%)	Control > 65 years (%)	Control >85 years (%)
<i>PSEN2</i>	Clinical Variant Carriers	4 (0.03%)	1 (0.01%)	1 (0.01%)	1 (0.02%)
	Conflicting Clinical Variant Carriers	95 (0.7%)	118 (0.8%)	115 (0.8%)	50 (1.1%)
	Additional LoF Variant Carriers	4 (0.03%)	1 (0.01%)	1 (0.01%)	0 (0%)
	Additional DM Variant Carriers	167 (1.2%)	180 (1.2%)	169 (1.2%)	54 (1.1%)
<i>PSEN1</i>	Clinical Variant Carriers	56 (0.4%)	2 (0.01%)	2 (0.01%)	0 (0%)
	Conflicting Clinical Variant Carriers	40 (0.3%)	40 (0.3%)	52 (0.3%)	10 (0.2%)
	Additional LoF Variant Carriers	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Additional DM Variant Carriers	39 (0.3%)	29 (0.2%)	25 (0.2%)	3 (0.06%)
<i>APP</i>	Clinical Variant Carriers	2 (0.01%)	0 (0%)	0 (0%)	0 (0%)
	Conflicting Clinical Variant Carriers	89 (0.6%)	112 (0.8%)	110 (0.8%)	38 (0.8%)
	Additional LoF Variant Carriers	1 (0.01%)	2 (0.01%)	2 (0.01%)	1 (0.02%)
	Additional DM Variant Carriers	159 (1.2%)	199 (1.4%)	174 (1.3%)	45 (1.0%)
Total		13,825	14,715	13,644	4722

Data shown as frequency (percentage).

LoF: Loss-of-function; DM: Damaging missense.

Table 4: Clinical Variants with Alternative Alleles Observed within the ADSP.

Gene	Chr:Position	rsID	REF	ALT	Protein Change	ClinVar	OMIM	Alzforum	gnomadAF*	Intervar Pathogenicity **	Mutation Type	Control	Case	Unknown
PSEN2	1:226883817	rs63750048	C	T	Ala85Val	1	1	0		LP	Missense	1	0	0
	1:226885603	rs63750215	A	T	Asn141Ile	1	1	1		LP	Missense	0	2	0
	1:226890097		A	G	Arg284Gly	0	0	1		NR	Missense	0	1	0
	1:226895548	rs63750110	A	C	Asp439Ala	0	1	0		UnS	Missense	0	1	1
PSEN1	14:73170945	rs63749824	C	T	Ala79Val	1	1	1	3.23E-05	LP	Missense	1	10	0
	14:73173570		T	C	Tyr115His	0	0	1		UnS	Missense	0	1	0
	14:73173571	rs63750450	A	G	Tyr115Cys	1	0	1		LP	Missense	0	0	1
	14:73173642	rs63751037	A	G	Met139Val	1	1	1		LP	Missense	0	2	0
	14:73173665		G	C	Met146Ile	0	0	1		LP	Missense	0	1	0
	14:73186860	rs63750590	A	G	His163Arg	1	1	1		LP	Missense	0	1	0
	14:73186868		C	G	Leu166Val	0	0	1		UnS	Missense	0	1	0
	14:73186904	rs63750155	T	C	Ser178Pro	0	0	1		UnS	Missense	0	1	0
	14:73192712	rs63750082	G	C	Gly206Ala	1	1	1		LP	Missense	1	21	4
	14:73192730	rs1555355250	C	A	Ser212Tyr	1	0	1		LP	Missense	0	1	0
	14:73192735	rs63751003	C	T	His214Tyr	0	0	1		UnS	Missense	0	1	0
	14:73192772	rs63749961	T	G	Leu226Arg	0	0	1		UnS	Missense	0	1	0
	14:73192792		A	C	Met233Leu	0	0	1		LP	Missense	0	1	0
	14:73192798	rs63751130	C	G	Leu235Val	0	0	1		UnS	Missense	0	0	1
	14:73192840	rs1362575880	A	C	Ile249Leu	1	0	0		NR	Missense	0	2	0
	14:73198042	rs63750964	G	T	Val261Phe	0	0	1		LP	Missense	0	1	0
	14:73198052	rs63750301	C	T	Pro264Leu	1	0	1		LP	Missense	0	1	1
	14:73198067	rs63750900	G	A	Arg269His	1	0	1		LP	Missense	0	4	0
	14:73206385	rs63750219	G	T	S290_S319delinsC G>T	1	1	1		NR	Deletion-Insertion	0	1	0
	14:73206385	rs63750219	G	A	S290_S319delinsC G>A	1	1	1		NR	Deletion-Insertion	0	0	3
	14:73217129	rs63750323	G	T	Gly378Val	0	0	1		LP	Missense	0	1	0
	14:73217182		G	A	Ala396Thr	0	0	1		UnS	Missense	0	1	0
	14:73217225	rs661	G	A	Cys410Tyr	1	1	1		LP	Missense	0	2	0
	14:73219161	rs63751223	G	C	Ala426Pro	1	1	1		LP	Missense	0	1	0
	14:73219177	rs63750083	C	A	Ala431Glu	1	1	1		LP	Missense	0	1	2
	APP	21:25891783	rs63749964	A	C	Val717Gly	0	1	0		LP	Missense	0	1
21:25891784		rs63750264	C	A	Val717Phe	1	1	0		LP	Missense	0	1	0

*Allele frequency from wInterVar annotation using the gnomAD exomes controls AF.

**UnS, Uncertain significance; NR, Not Reported; LP, Likely Pathogenic.

***Variant positions were based on Genome Reference Consortium Human Build 38 (GRCh 38).

Figure legends

Figure 1. Flow Chart of the Analysis.

Figure 1 represents the schematic of the analysis. ADSP whole genome sequencing data and whole exome sequencing data were combined, and variants with $MAF < 1\%$ in *PSEN2*, *PENSI*, and *APP* genes were extracted. Subsequently, VEP and dbNFSP annotation was conducted to identify the additional loss-of-function (LoF) and damaging missense (DM) variants in the ADSP participants, followed by the curation of clinical variants from ClinVar, OMIM, and Alzforum databases. We then reported demographic and AD status of the carriers of these variants.

Figure 2. Age of AD Onset Among Carriers and Non-Carriers.

Boxplot showing the age of AD onset in years among the carriers and non-carriers of clinical, conflicting clinical, additional LoF, or additional DM variants. The mean and standard deviation (SD) of age of AD onset are 55.98 ± 10.88 years for clinical variant carriers, 70.60 ± 13.78 years for additional LoF variant carriers, 76.30 ± 9.30 for conflicting clinical variant carriers, 75.28 ± 9.73 for additional DM variant carriers, and 75.56 ± 9.48 for non-carriers. Linear mixed models adjusted for sex and the first four principal components, accounting for an empirical Balding-Nichols kinship matrix were used to contrast the mean age of AD onset between: 1) clinical variant carriers and non-carriers; 2) clinical variant carriers + additional LoF variant carriers and non-carriers. The exact p-values for the two comparisons are $7.79e^{-57}$ and $1.10e^{-54}$. *** denotes $p\text{-value} < 0.001$.

Figure 1. Flow Chart of the Analysis.





Figure 2. Age of AD Onset Among Carriers and Non-Carriers.



Appendix 1

Name	Location	Contribution
Dongyu Wang, MS, MPH	Boston University School of Public Health, Boston, MA	Analyzed the data; drafted the manuscript
Alexandra Scalici, MPH	Boston University School of Public Health, Boston, MA	Analyzed the data
Yanbing Wang, PhD	Boston University School of Public Health, Boston, MA	Analyzed the data
Honghuang Lin, PhD	University of Massachusetts Chan Medical School, Worcester, MA, 01655, USA.	Analyzed the data; revised the manuscript for intellectual content
Achilleas Pitsillides, PhD	Boston University School of Public Health, Boston, MA	Analyzed the data
Nancy Heard-Costa, PhD	Boston University School of Medicine, Boston, MA	Analyzed the data
Carlos Cruchaga, PhD	Washington University School of Medicine, St. Louis, MO	Revised the manuscript for intellectual content
Ellen Ziegemeier, MA	Washington University School of Medicine, St. Louis, MO	Interpreted the data; revised the manuscript for intellectual content
Joshua C. Bis, PhD	University of Washington, Seattle, WA	revised the manuscript for intellectual content
Myriam Fornage, PhD	The University of Texas Health Science Center at Houston, Houston, TX	Revised the manuscript for intellectual content
Eric Boerwinkle, PhD	The University of Texas Health Science Center at Houston, Houston, TX	Revised the manuscript for intellectual content
Philip L De Jager, MD, PhD	Columbia University Medical Center, New York, NY	Revised the manuscript for intellectual content
Ellen Wijsman, PhD	University of Washington, Seattle, WA	Interpreted the data; revised manuscript for intellectual content
Josée Dupuis, PhD	Boston University School of Public Health, Boston, MA	Interpreted the data; revised the manuscript for intellectual content
Alan E. Renton, PhD	Icahn School of Medicine at Mount Sinai, New York, NY	Interpreted the data; revised the manuscript for intellectual content
Sudha Seshadri, MD	University of Texas Health San Antonio, San Antonio, TX, USA	Interpreted the data; revised the manuscript for intellectual content

Alison Goate, DPhil	Icahn School of Medicine at Mount Sinai, New York, NY	Interpreted the data; revised the manuscript for intellectual content
Anita L. DeStefano, PhD	Boston University School of Public Health, Boston, MA	Design and conceptualized study; Interpreted the data; revised the manuscript for intellectual content
Gina M. Peloso, PhD	Boston University School of Public Health, Boston, MA	Design and conceptualized study; Analyzed and interpreted the data; revised the manuscript for intellectual content

REFERENCES

1. Chouraki V, Seshadri S. Genetics of alzheimer's disease. *Adv Genet.* 2014;87:245-294. doi: 10.1016/B978-0-12-800149-3.00005-6.
2. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset alzheimer's disease families. *PLoS One.* 2012;7(2):e31039. doi: 10.1371/journal.pone.0031039.
3. Lanoiselee H, Nicolas G, Wallon D, et al. APP, PSEN1, and PSEN2 mutations in early-onset alzheimer disease: A genetic screening study of familial and sporadic cases. *PLoS Med.* 2017;14(3):e1002270. doi: 10.1371/journal.pmed.1002270.
4. Beecham GW, Bis JC, Martin ER, et al. The alzheimer's disease sequencing project: Study design and sample selection. *Neurol Genet.* 2017;3(5):e194. doi: 10.1212/NXG.0000000000000194.
5. Naj AC, Lin H, Vardarajan BN, et al. Quality control and integration of genotypes from two calling pipelines for whole genome sequence data in the alzheimer's disease sequencing project. *Genomics.* 2019;111(4):808-818. doi: 10.1016/j.ygeno.2018.05.004.
6. Leung YY, Valladares O, Chou Y, et al. VCPA: Genomic variant calling pipeline and data management tool for alzheimer's disease sequencing project. *Bioinformatics.* 2019;35(10):1768-1770. doi: 10.1093/bioinformatics/bty894.

7. Blue EE, Bis JC, Dorschner MO, et al. Genetic variation in genes underlying diverse dementias may explain a small proportion of cases in the alzheimer's disease sequencing project. *Dement Geriatr Cogn Disord*. 2018;45(1-2):1-17. doi: 10.1159/000485503.
8. Fernandez MV, Kim JH, Budde JP, et al. Analysis of neurodegenerative mendelian genes in clinically diagnosed alzheimer disease. *PLoS Genet*. 2017;13(11):e1007045. doi: 10.1371/journal.pgen.1007045.
9. PLINK 2 KING Relative Cut-off. Updated 2023. Accessed March 3, 2023. https://www.cog-genomics.org/plink/2.0/distance#make_king.
10. Landrum MJ, Lee JM, Benson M, et al. ClinVar: Improving access to variant interpretations and supporting evidence. *Nucleic Acids Res*. 2018;46(D1):D1062-D1067. doi: 10.1093/nar/gkx1153.
11. Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): A knowledgebase of human genes and genetic phenotypes. *Curr Protoc Bioinformatics*. 2017;58:1.2.1-1.2.12. doi: 10.1002/cpbi.27.
12. Alzforum Mutation list. Updated 2023. Accessed February 17, 2023. <https://www.alzforum.org/mutations>.
13. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: Rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7-8. eCollection 2015. doi: 10.1186/s13742-015-0047-8.

14. McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. *Genome Biol.* 2016;17(1):122-4. doi: 10.1186/s13059-016-0974-4.
15. Liu X, Jian X, Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. *Hum Mutat.* 2011;32(8):894-899. doi: 10.1002/humu.21517.
16. Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: A comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. *Genome Med.* 2020;12(1):103-9. doi: 10.1186/s13073-020-00803-9.
17. Li Q, Wang K. InterVar: Clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. *Am J Hum Genet.* 2017;100(2):267-280. doi: 10.1016/j.ajhg.2017.01.004.
18. Arboleda-Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant alzheimer's disease in an APOE3 christchurch homozygote: A case report. *Nat Med.* 2019;25(11):1680-1683. doi: 10.1038/s41591-019-0611-3.
19. Xiao X, Liu H, Liu X, Zhang W, Zhang S, Jiao B. APP, PSEN1, and PSEN2 variants in alzheimer's disease: Systematic re-evaluation according to ACMG guidelines. *Front Aging Neurosci.* 2021;13:695808. doi: 10.3389/fnagi.2021.695808.
20. Popejoy AB, Ritter DI, Crooks K, et al. The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics. *Hum Mutat.* 2018;39(11):1713-1720. doi: 10.1002/humu.23644.

21. Manrai AK, Funke BH, Rehm HL, et al. Genetic misdiagnoses and the potential for health disparities. *N Engl J Med*. 2016;375(7):655-665. doi: 10.1056/NEJMsa1507092.

22. Spratt DE, Chan T, Waldron L, et al. Racial/ethnic disparities in genomic sequencing. *JAMA Oncol*. 2016;2(8):1070-1074. doi: 10.1001/jamaoncol.2016.1854.